ECM
RGLS

Element Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Element Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-504
Closed -$76K – 154
2017
Q3 		$76K Sell
504
-859
-63% -$108K 0.03% 55
2017
Q2 		$161K Buy
+1,363
New +$228K 0.03% 109

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Element Capital Management's RGLS Position: Q4 2017 in Review

Element Capital Management sold out of Regulus Therapeutics (RGLS) in Q4 2017, closing a stake of 504 shares — an estimated $76K sold.

Element Capital Management first reported a position in RGLS in Q2 2017 and held it in 2 quarters. The position peaked at $161K in Q2 2017. 49 funds tracked by Wall St. Rank hold RGLS as of Q4 2017.

  • Element Capital Management reported no remaining Regulus Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Element Capital Management sold 504 Regulus Therapeutics shares in Q4 2017, an estimated $76K.
  • Element Capital Management first reported a position in Regulus Therapeutics in Q2 2017 and held it in 2 quarters.
  • Element Capital Management's Regulus Therapeutics position peaked at $161K in Q2 2017.
  • 49 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2017.

Based on Element Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.